The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
August 29th 2025
A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.
Expanding Access to Whole Genome Sequencing in Parkinson Research: James Beck, PhD
April 17th 2025The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]
Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease
April 3rd 2025Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.
Balancing Approved Therapies and Patient Preference in Parkinson Disease
March 28th 2025An expert discusses the importance of collaborating with patients, emphasizing the value of leading with data when educating them on the efficacy of treatments, and highlights the role of providers in supporting patients as they discover the medications and supplements that work best for them, while advocating for and protecting patients to ensure they can seek the best quality of life.
Providing a Holistic Approach to Parkinson Disease Care
March 28th 2025An expert discusses the various forms of therapy offering nutritional support, including exercise and supplements, emphasizing that supplemental therapy, along with medication, is most effective, and highlights the potential benefits of the Mediterranean diet for Parkinson disease.
Exciting Pipeline Therapeutics for Parkinson Disease
March 21st 2025An expert discusses upcoming advancements in Parkinson disease treatments, including the potential release of the ND0612 pump later this year, demonstrating efficacy comparable to oral carbidopa/levodopa, the dopamine agonist tavapadon, CVN424 as a novel therapy not targeting the dopamine pathway, and ongoing stem cell and gene therapy developments, with stem cells capable of creating dopamine-producing cells entering phase 3 studies.
Recent Medical Advancements: Opportunities and Considerations
March 14th 2025An expert discusses the extended form of carbidopa/levodopa (Crexont) for managing OFF episodes, highlighting trial results that show decreased OFF time and increased ON time, as well as the use of subcutaneous loading of medications in Parkinson disease, which was well tolerated with skin issues as the main adverse effects and resulted in increased ON time without worsening dyskinesia.
Parkinson Disease: Prevalence and Impact of OFF Episodes and Dyskinesia
March 14th 2025An expert discusses how providers can accurately track episodes of OFF and dyskinesia, highlighting their impact on patients physically, socially, and psychologically, including the challenges dyskinesia poses for sleep and fine motor tasks.
Evolving Parkinson Disease Care in the Digital Age of Neurology: Sheryll Baltazar, NP-C
February 17th 2025The nurse practitioner at the Parkinson’s and Movement Disorders Center at Stony Brook Medicine discussed the increasing role of artificial intelligence in neurology, specifically movement disorders. [WATCH TIME: 5 minutes]
Reducing OFF Time in Parkinson Disease With SPN-830 Infusion Therapy: Julie Pilitsis, MD, PhD, MBA
February 13th 2025The chair of neurosurgery at the University of Arizona talked about the newly approved infusion therapy that offers continuous medication delivery to improve both motor and non-motor symptoms in Parkinson disease. [WATCH TIME: 5 minutes]
Using Practical Training to Enhance Movement Disorder Care: Clarisse Goas MSN, APRN-CNP
February 7th 2025The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]
Mechanism and Promise Behind SPN-830 for Parkinson Disease: Stuart Isaacson, MD, FAAN
February 7th 2025The director of the Parkinson’s Disease and Movement Disorders Center of Boca Roaton, Florida, gave clinical insight on the function of a newly approved therapy for Parkinson disease, a common neurodegenerative disorder. [WATCH TIME: 3 minutes]
Reaction and Significance of SPN-830 Approval for Parkinson Disease: Stuart Isaacson, MD, FAAN
February 5th 2025The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, discussed SPN-830, the first and only FDA-approved subcutaneous apomorphine infusion device for patients with Parkinson disease. [WATCH TIME: 2 minutes]
FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment
Published: February 4th 2025 | Updated: February 6th 2025SPN-830 is a wearable subcutaneous infusion device designed to deliver continuous treatment throughout the waking day, ensuring more consistent control of OFF time.
Implementing MRI-Guided Focused Ultrasound: Challenges and Opportunities
January 28th 2025Neurologists Steven Lewis, MD, and Behrang Saminejad, MD, of Lehigh Valley Health Network, provided commentary on the ways to successfully implement focused ultrasound as a treatment for essential tremor and Parkinson disease.